[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20070106A1 - Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr - Google Patents

Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr

Info

Publication number
PE20070106A1
PE20070106A1 PE2006000589A PE2006000589A PE20070106A1 PE 20070106 A1 PE20070106 A1 PE 20070106A1 PE 2006000589 A PE2006000589 A PE 2006000589A PE 2006000589 A PE2006000589 A PE 2006000589A PE 20070106 A1 PE20070106 A1 PE 20070106A1
Authority
PE
Peru
Prior art keywords
alkyl
absent
pharmaceutical compositions
compositions containing
present
Prior art date
Application number
PE2006000589A
Other languages
English (en)
Inventor
Anima Ghosal
Narendra S Kishnani
Kevin B Alton
Ronald E White
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070106A1 publication Critical patent/PE20070106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPETIDOR DE LA ALDO-CETO REDUCTASA (AKR) SELECCIONADO ENTRE DOLASETRON, DOXORUBICINA, FIBRATO, ANTIINFLAMATORIO NO ESTEROIDE, ENTRE OTROS; B) UN COMPUESTO, ENTRE OTROS, DE FORMULA I, DONDE Y ES ALQUILO, ALQUIL-ARILO, ALQUILOXI, ARILOXI, HETEROARILAMINO, ENTRE OTROS; R1 ES COCONHR9; R9 ES H, ALQUILO, ARILO, HETEROALQUILO, CICLOALQUILO, ENTRE OTROS; Z ES O, N, CH, ENTRE OTROS; W PUEDE ESTAR AUSENTE O NO Y ES CO, CS, SO2, ENTRE OTROS; Q ES CH, P, S, SO2, ENTRE OTROS; A ES O, CH2, S, SO2, UN ENLACE, ENTRE OTROS; E ES CH, N, UN ENLACE DOBLE HACIA A, L, G, ENTRE OTROS; G ESTA PRESENTE O AUSENTE Y ES (CH2)p, (CHR)p, NR, ENTRE OTROS; J ES (CH2)p, (CHR)p, SO2, NH, NR, O, ENTRE OTROS; L ES PUEDE ESTAR PRESENTE O AUSENTE Y ES CH, CR, O, S, NR; M PUEDE ESTAR PRESENTE O AUSENTE Y ES O, NR, S, SO2, (CH2)p, ENTRE OTROS; p ES 0-6; R, R2, R3 Y R4 SON CADA UNO H, ALQUILO C1-C10, ALQUENILO C2-C10, CICLOALQUILO C3-C8, ALCOXI, ENTRE OTROS. UN COMPUESTO PREFERIDO ES A. DICHAS COMPOSICIONES SON UTILES EN EL TRATAMIENTO O PREVENCION DE LA HEPATITIS C Y DESORDENES RELACIONADOS CON EL VIRUS VHC
PE2006000589A 2005-06-02 2006-06-01 Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr PE20070106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68692405P 2005-06-02 2005-06-02

Publications (1)

Publication Number Publication Date
PE20070106A1 true PE20070106A1 (es) 2007-04-16

Family

ID=36954846

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000589A PE20070106A1 (es) 2005-06-02 2006-06-01 Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr

Country Status (5)

Country Link
US (1) US20060276404A1 (es)
AR (1) AR054197A1 (es)
PE (1) PE20070106A1 (es)
TW (1) TW200724154A (es)
WO (1) WO2006130666A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1891089B1 (en) * 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20090148407A1 (en) * 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
NZ568135A (en) 2005-10-11 2011-06-30 Array Biopharma Inc Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1998759A2 (en) * 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CL2008001381A1 (es) 2007-05-10 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
JP2011503231A (ja) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染処置のためのペプチド
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
TWI487522B (zh) 2007-12-21 2015-06-11 賽基艾維洛米斯研究股份有限公司 Ｈｃｖ蛋白酶抑制劑及其用途（一）
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
BR112013016480A2 (pt) 2010-12-30 2016-09-20 Abbvie Inc macrocíclo da fenantridina inibadores da protease da serina da hepatite c
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102836433A (zh) * 2011-06-23 2012-12-26 北京大学 逆转或降低食管癌放疗抗性的增敏剂、筛选方法及其用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
ES2527510T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
WO2014033667A1 (en) * 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
EP2909205B1 (en) 2012-10-19 2016-11-23 Bristol-Myers Squibb Company 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110220757B (zh) * 2019-06-05 2021-08-24 浙江龙传生物医药科技有限公司 用于药物代谢检测的血液保存剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) * 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
RU2003105221A (ru) * 2000-07-21 2004-09-20 Шеринг Корпорейшн (US) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
IL162828A0 (en) * 2002-01-23 2005-11-20 Schering Corp Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
JP4823899B2 (ja) * 2003-06-17 2011-11-24 シェーリング コーポレイション ３−（アミノ）−３−シクロブチルメチル−２−ヒドロキシ−プロピオンアミドまたはその塩の調製のためのプロセスおよび中間体
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
SG180022A1 (en) * 2003-06-17 2012-05-30 Schering Corp Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
CN1867579A (zh) * 2003-08-26 2006-11-22 先灵公司 丙肝病毒的新的肽模拟物ns3－丝氨酸蛋白酶抑制剂
WO2005051980A1 (en) * 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
PE20050940A1 (es) * 2003-12-11 2005-11-08 Schering Corp Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
PE20050999A1 (es) * 2004-02-27 2005-12-01 Schering Corp Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
MY145081A (en) * 2004-02-27 2011-12-15 Schering Corp Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087730A1 (en) * 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
KR20060127162A (ko) * 2004-02-27 2006-12-11 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의화합물
CN1946690A (zh) * 2004-02-27 2007-04-11 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物
KR20060124729A (ko) * 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의신규한 화합물
JP4745327B2 (ja) * 2004-02-27 2011-08-10 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
DE602005015452D1 (de) * 2004-05-20 2009-08-27 Schering Corp Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus

Also Published As

Publication number Publication date
AR054197A1 (es) 2007-06-06
US20060276404A1 (en) 2006-12-07
TW200724154A (en) 2007-07-01
WO2006130666A3 (en) 2007-06-21
WO2006130666A2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
PE20070106A1 (es) Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr
PE20080197A1 (es) Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
PE20030857A1 (es) Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20050370A1 (es) Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c
PE20050999A1 (es) Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
PE20030852A1 (es) Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
ECSP066456A (es) Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c
PE20070011A1 (es) Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
ATE334654T1 (de) Vor uv-strahlen schützende zusammensetzungen
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
UY27638A1 (es) Compuesto inhibidor de la hepatitis c
PE20070343A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
NO20075809L (no) DNA-PK inhibitorer
EA200800485A1 (ru) Макроциклические ингибиторы вируса гепатита с
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
HRP20130075T1 (hr) S-TRIAZOLIL ALFA-MERKAPTOACETANILIDI KAO INHIBITORI REVERZNE TRANSKRIPTAZE HIV-a
BRPI0606480A (pt) compostos farmacêuticos
NO20080879L (no) HCV-NS3-proteaseinhibitorer
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
AR057325A1 (es) Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
MX2010003261A (es) Analogos de azacitidina y usos de los mismos.
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal